By most standards, Covidien (NYSE: COV )
has been a superior performer in the med-tech sector. That hasn't
always shown up in the company's stock performance, however, as rebound
stories like St. Jude Medical, Boston Scientific, and Bard have
raced ahead. With Covidien announcing a noisy quarter with some
apparent seasonal pressures on Friday, it looks as though Fools have an
opportunity to add shares in a high-quality name at a pretty interesting
valuation.
Continue here:
Do Disappointing Earnings Create a Good Buying Opportunity?
No comments:
Post a Comment